SILOHealthcare · BiotechnologySILO Stock Forecast: Silo Pharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 1 Aug 2026 — in the weakest quartile.
SILO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Silo Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Silo Pharma, Inc. — and when they’d sell — is the membership.
SILO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SILO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2023 | Laidlaw & Co. | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SILO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Silo Pharma, Inc. (SILO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.6×
- Price / sales
- 65.6×
- Price / book
- 0.8×
- EV / EBITDA
- 0.3×
Cheaper than 80% of US stocks
Cheaper than 5% of US stocks
Cheaper than 78% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- 0.0%
- Earnings growth (YoY)
- 0.0%
- Gross margin
- −14.8%
- Operating margin
- −8846.4%
- Net margin
- 38.6%
Higher than 29% of US stocks
Higher than 36% of US stocks
Higher than 4% of US stocks
Higher than 2% of US stocks
Higher than 93% of US stocks
- Return on equity
- −99.9%
- Return on assets
- −46.3%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SILO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SILO appears on the weeks it earns a place.
Frequently asked questions about SILO stock
How does Ticker Nerd's model rank SILO?
As at 1 Aug 2026, Silo Pharma, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
What is the SILO stock forecast for 2030?
No analyst covering Silo Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SILO are extrapolating price history, which says nothing about the business.
How has SILO stock performed over the past year?
Silo Pharma, Inc. returned -60.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Silo Pharma, Inc. do?
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system diseases such as Alzheimer's and multiple sclerosis.
About Silo Pharma, Inc.
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system diseases such as Alzheimer's and multiple sclerosis. The company merges traditional therapies with psychedelic medicine, utilizing innovative formulations and drug delivery systems like intranasal treatments and time-release implants. Its lead program, SPC-15, is an intranasal formulation targeting PTSD and stress-induced anxiety. SP-26 is a ketamine-based injectable dissolvable implant designed for fibromyalgia and chronic pain relief. Preclinical efforts include SPC-14, an intranasal compound for Alzheimer's disease, and SPU-16, a CNS-homing peptide for multiple sclerosis. Silo Pharma acquires intellectual property from universities and researchers, pursuing streamlined clinical pathways. Founded in 2010 and headquartered in Sarasota, Florida, the company partners with leading academic institutions to advance its pipeline of psychedelic and conventional treatments for psychiatric and neurological disorders.
CEO Mr. Eric Weisblum · 3 employees · United States · https://silopharma.com